Article Text

Download PDFPDF

Intervention in acute coronary syndromes: do patients undergo intervention on the basis of their risk characteristics? The Global Registry of Acute Coronary Events (GRACE)
Free
  1. K A A Fox1,
  2. F A Anderson Jr2,
  3. O H Dabbous2,
  4. P G Steg3,
  5. J López-Sendón4,
  6. F Van de Werf5,
  7. A Budaj6,
  8. E P Gurfinkel7,
  9. S G Goodman8,
  10. D Brieger9,
  11. on behalf of the GRACE investigators
  1. 1Cardiovascular Research, Division of Medical & Radiological Sciences, The University of Edinburgh, Edinburgh, UK
  2. 2Center for Outcomes Research, University of Massachusetts Medical School, Worcester, Massachusetts, USA
  3. 3Cardiology, Hôpital Bichat, Paris, France
  4. 4Department of Cardiology, Hospital Universitario La Paz, Madrid, Spain
  5. 5Department of Cardiology, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
  6. 6Postgraduate Medical School, Grochowski Hospital, Warsaw, Poland
  7. 7Department of Cardiology, ICYCC Favaloro Foundation, Buenos Aires, Argentina
  8. 8Canadian Heart Research Centre and Terrence Donnelly Heart Centre, Division of Cardiology, St Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada
  9. 9Coronary Care Unit, Concord Hospital, Sydney, Australia
  1. Correspondence to:
    Professor Keith A A Fox
    Cardiovascular Research, University of Edinburgh, Chancellor’s Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK; k.a.a.fox{at}ed.ac.uk

Abstract

Objective: To determine whether revascularisation is more likely to be performed in higher-risk patients and whether the findings are influenced by hospitals adopting more or less aggressive revascularisation strategies.

Methods: GRACE (Global Registry of Acute Coronary Events) is a multinational, observational cohort study. This study involved 24 189 patients enrolled at 73 hospitals with on-site angiographic facilities.

Results: Overall, 32.5% of patients with a non-ST elevation acute coronary syndrome (ACS) underwent percutaneous coronary intervention (PCI; 53.7% in ST segment elevation myocardial infarction (STEMI)) and 7.2% underwent coronary artery bypass grafting (CABG; 4.0% in STEMI). The cumulative rate of in-hospital death rose correspondingly with the GRACE risk score (variables: age, Killip class, systolic blood pressure, ST segment deviation, cardiac arrest at admission, serum creatinine, raised cardiac markers, heart rate), from 1.2% in low-risk to 3.3% in medium-risk and 13.0% in high-risk patients (c statistic  =  0.83). PCI procedures were more likely to be performed in low- (40% non-STEMI, 60% STEMI) than medium- (35%, 54%) or high-risk patients (25%, 41%). No such gradient was apparent for patients undergoing CABG. These findings were seen in STEMI and non-ST elevation ACS, in all geographical regions and irrespective of whether hospitals adopted low (4.2−33.7%, n  =  7210 observations), medium (35.7−51.4%, n  =  7913 observations) or high rates (52.6−77.0%, n  =  8942 observations) of intervention.

Conclusions: A risk-averse strategy to angiography appears to be widely adopted. Proceeding to PCI relates to referral practice and angiographic findings rather than the patient’s risk status. Systematic and accurate risk stratification may allow higher-risk patients to be selected for revascularisation procedures, in contrast to current international practice.

  • CABG, coronary artery bypass grafting
  • GRACE, Global Registry of Acute Coronary Events
  • ICTUS, Invasive versus Conservative Treatment in Unstable Coronary Syndromes
  • NSTEMI, non-ST segment elevation myocardial infarction
  • PCI, percutaneous coronary intervention
  • STEMI, ST segment elevation myocardial infarction

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Published Online First 6 June 2006

  • GRACE is supported by an unrestricted educational grant from sanofi-aventis, Paris, France.

  • Competing interests: KAAF: British Heart Foundation, Medical Research Council, Wellcome Trust, sanofi-aventis; FAA: sanofi-aventis; OHD: no conflicts to disclose; PGS: sanofi-aventis; JL-S: sanofi-aventis, Pfizer, the TIMI group, BMS, Medtronic and Guidant; FV: Boehringer Ingelheim, sanofi-aventis, Proctor and Gamble, Servier, Novartis, MSD and Schering Plough; A Budaj: sanofi-aventis; EPG: sanofi-aventis, Lilly and Astra Zeneca; SGG: sanofi-aventis, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Glaxo Smith Kline, Hoffmann-LaRoche Pharmaceuticals, Merck & Co, Inc, Novartis, Pfizer Inc, Sanofi-Synthelabo, Schering Corporation, Millennium Pharmaceuticals, Inc and The Medicines Company; DB: sanofi-aventis.

  • Author contributors: Conception and design: KAA Fox, FA Anderson, PG Steg, J López-Sendón, F Van de Werf, A Budaj, EP Gurfinkel, SG Goodman, D Brieger; analysis and interpretation of the data: KAA Fox, OH Dabbous, PG Steg, J López-Sendón, F Van de Werf, A Budaj, EP Gurfinkel, SG Goodman, D Brieger; drafting of the article: KAA Fox, OH Dabbous; critical revision of the article for important intellectual content: KAA Fox, FA Anderson, OH Dabbous, PG Steg, J López-Sendón, F Van de Werf, A Budaj, EP Gurfinkel, SG Goodman, D Brieger; final approval of the article: KAA Fox, FA Anderson, OH Dabbous, PG Steg, J López-Sendón, F Van de Werf, A Budaj, EP Gurfinkel, SG Goodman, D Brieger; statistical expertise: OH Dabbous; obtaining funding: FA Anderson; collection and assembly of data: KAA Fox, PG Steg, J López-Sendón, F Van de Werf, A Budaj, EP Gurfinkel, SG Goodman, D Brieger.

Linked Articles

  • Miscellanea
    BMJ Publishing Group Ltd and British Cardiovascular Society